Hepatology
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →Splenic Elastography as a Predictor of Gastroesophageal Varices in Cirrhosis.
Clinical takeawayNo clinical action yet: a moderate-accuracy noninvasive predictor in a single-center study needs external validation before replacing endoscopy.
What it foundSplenic elastography (≥27 kPa cutoff) predicted gastroesophageal varices with AUC 0.72, sensitivity 82%, specificity 67%, and median stiffness rose from 25 kPa (no varices) to 50 kPa (large varices).
ContextConfirms splenic elastography correlates with variceal size but does not yet match endoscopy's role in variceal screening.
Emergingsuggested applicable standard· AASLD, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease" (Rinella ME et al., Hepatology 2023;77(5):1797-1835). DOI 10.1097/HEP.0000000000000323, PMID 36727674.
Decision at stakepredicting gastroesophageal varices in cirrhosis
AASLD, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease" (Rinella ME et al., Hepatology 2023;77(5):1797-1835). DOI 10.1097/HEP.0000000000000323, PMID 36727674. · reviewed 2026-07-21 ↗Statins are safe and recommended in MASLD/MASH and compensated cirrhosis when indicated for cardiovascular risk reduction. Start per standard CV risk-based criteria with baseline LFTs; routine ALT monitoring on statin is not required and pre-existing transaminitis is not a contraindication. Hold or reduce only for clinically significant ALT elevation, severe muscle symptoms, or decompensated cirrhosis on an individualized basis.
Pacheco Oliva J … Sánchez Orozco AA · Clinical and Translational Gastroenterology · IF 3.4 · PubMed ↗